GH Research Future Growth
Future criteria checks 0/6
GH Research's earnings are forecast to decline at 26.7% per annum while its annual revenue is expected to grow at 80.5% per year. EPS is expected to decline by 20.8% per annum. Return on equity is forecast to be -37.7% in 3 years.
Key information
-26.7%
Earnings growth rate
-20.8%
EPS growth rate
| Pharmaceuticals earnings growth | 17.9% |
| Revenue growth rate | 80.5% |
| Future return on equity | -37.7% |
| Analyst coverage | Low |
| Last updated | 06 Sep 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -89 | -117 | -114 | 3 |
| 12/31/2025 | N/A | -75 | -64 | -62 | 5 |
| 12/31/2024 | N/A | -45 | -40 | -39 | 5 |
| 6/30/2024 | N/A | -35 | -38 | -38 | N/A |
| 3/31/2024 | N/A | -32 | -36 | -36 | N/A |
| 12/31/2023 | N/A | -36 | -33 | -33 | N/A |
| 9/30/2023 | N/A | -41 | -32 | -32 | N/A |
| 6/30/2023 | N/A | -36 | -30 | -30 | N/A |
| 3/31/2023 | N/A | -28 | -27 | -27 | N/A |
| 12/31/2022 | N/A | -22 | -26 | -26 | N/A |
| 9/30/2022 | N/A | -10 | -23 | -23 | N/A |
| 6/30/2022 | N/A | -11 | -24 | -24 | N/A |
| 3/31/2022 | N/A | -14 | -20 | -20 | N/A |
| 12/31/2021 | N/A | -9 | -15 | -15 | N/A |
| 9/30/2021 | N/A | -5 | -12 | -12 | N/A |
| 6/30/2021 | N/A | -4 | -3 | -3 | N/A |
| 3/31/2021 | N/A | -2 | -1 | -1 | N/A |
| 12/31/2020 | N/A | 0 | 0 | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1KA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 1KA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 1KA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 1KA is forecast to have no revenue next year.
High Growth Revenue: 1KA is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1KA is forecast to be unprofitable in 3 years.